RBCC Explores New Funding for Expansion Business Wire NOKOMIS, Fla. -- June 10, 2013 As Rainbow Coral Corp. (OTCBB: RBCC) pushes forward with its aggressive expansion strategy for 2013, the company is considering promising new funding opportunities in order to deliver cutting-edge innovations to the $232 billion personalized medicine market. RBCC is already poised for rapid growth this year. The company recently signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before, and is currently in negotiations to partner with an emerging innovator in the transdermal delivery sector, as well. Last month, RBCC’s joint venture partner, Nano3D BioSciences, announced a distribution agreement with St. Louis-based scientific products distributor MIDSCI to sell its revolutionary BioAssembler product line in the multi-billion-dollar U.S biotechnology market. To continue expanding its marketing and development efforts, RBCC will explore new funding opportunities in order to capitalize on the unprecedented rise of the biotechnology sector. “Our company is now well-positioned in a robust marketplace, and new funding opportunities are opening up for us every day,” said RBCC CEO Patrick Brown. “We’re carefully considering our options in order to ensure that we’re able to accomplish the goals that we’ve set for ourselves this year.” For more information on RBCC’s partnership with n3D and other biotech initiatives, please visitwww.rainbowbiosciences.com/investors.html. Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT) and Amgen Inc. (NASDAQ:AMGN). About Rainbow BioSciences Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visitwww.RainbowBioSciences.com. For investment information and performance data on the Company, please visitwww.RainbowBioSciences.com/investors.html. Notice Regarding Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof. Contact: Rainbow Coral Corp. Patrick Brown, 850-269-7230 President and CEO email@example.com
German November IFO Confidence at 104.7; Median Forecast 103.0
RBCC Explores New Funding for Expansion
Press spacebar to pause and continue. Press esc to stop.